Skip to content

Health Economic Modeling

Cost-Effectiveness Models

Core cost-effectiveness models are needed for a growing number of countries to support local HTA submissions.

Our multidisciplinary team of modelers, SLR specialists, ITC specialists, and biostatisticians always start with a targeted strategy before building the core cost-effectiveness model. This strategy is typically based on the following types of information: pivotal trial results in terms of disease progression, survival quality of life and medical resource use, network meta-analyses, SLRs, previous HTA submissions, competitive landscape and guidelines in clinical practice, published quality of life, medical resource use estimates, and our thorough understanding of different modeling approaches and diseases.

Based on this multidisciplinary strategy, Cytel's HEOR team has successfully developed cost-effectiveness models (CEM/CEA) and cost-utility models (CUA) for numerous indications in oncology, cardiovascular, orphan, and numerous other chronic and acute diseases. Our experts have effectively developed standard and advanced cost-effectiveness models resulting in successful reimbursement submissions. These include decision-tree, Markov models, dynamic models for infectious diseases, multistate models, landmark models, and micro-simulation models.

line-bg
_Budget impact scenarios_580x474px
Early models Read more
Local adaptations Read more

Budget Impact Models

Budgets are an increasing concern for national, local, and regional healthcare purchasers. Cytel will help you select the right budget impact model (BIM), an interface for the right audience, or both.

BIMs help purchasers evaluate the affordability of new products as they are introduced to the market. They can be used when considering reimbursement at the national level, and are useful for facilitating discussions with local stakeholders.

Cytel develops the right BIM for the right audience: simple health economic models for reimbursement purposes, and interactive, user-friendly models for discussions with local stakeholders.

Screen Shot 2022-06-09 at 3.15.38 PM
leftside leftside Health Econominc Modelling(1)_580x302px

Cost-Consequence Models

Where the key requirement for payers’ evidence is centered on short-term cost consequences or cost-offsets associated with introducing a new intervention, our team can help. Our Cost-consequence models (CCMs) and Cost outcomes models (COMs) are simple to understand and user-friendly. They clearly present the short-term cost implications to payers such as health insurers of altering the make-up of their formulary to incorporate a novel intervention.

Our Economic Publications

2021
2020
2019
2018
2012
2011
2010
2009
2008
leftside leftside Screenshot 2022-04-08 at 10.56.27

Why Cytel

We typically program our models in Excel and Visual Basic or R. The nice feature or our R models is that they can be converted with full VBA functionality to Excel. This is important as there is a trend towards R based models in developed HTA countries but numerous HTAs still prefer Excel and Visual Basics.

Our Software

We typically program our models in Excel and Visual Basic or R. The nice feature or our R models is that they can be converted with full VBA functionality to Excel. This is important as there is a trend towards R-based models in developed HTA countries but numerous HTAs still prefer Excel and Visual Basics

CEM Apps

Cytel’s cost-effectiveness model (CEM) apps are custom-made, payer-facing communication tools. Delivered via an Excel spreadsheet with a graphic user interface (GUI), our CEM apps improve communication capabilities and are significantly more user-friendly than conventional economic models.

BIM Apps

Cytel’s budget impact model (BIM) apps are created for users without a background in modeling. They reduce internal learning time with user-friendly, storytelling interfaces and relevant value story arguments. Navigation, presentation, and other functional capabilities are made accessible through graphic data visualization. The original Excel models are retained to meet any transparency requirements. 

Meet Our Economic Experts

Bart Heeg-1 (1) (1)

Bart Heeg

VP, Global HEOR
GABRIEL TREMBLAY-3

Gabriel Tremblay

VP Advanced Analytics
Peter Wigfield-1

Peter Wingfield

Associate Director, HEOR
Susannah Sadler

Susannah Sadler

Associate Director, HEOR